BeOne Medicines Ltd. Cash & Equivalents 2013-2026 | ONC
What is cash & equivalents?
Cash and cash equivalents can be defined as the most liquid assets on a company's balance sheet, including cash on hand and short-term investments maturing within 90 days.
What is BeOne Medicines Ltd.'s current cash & equivalents?
BeOne Medicines Ltd. (ONC) annual cash & equivalents for 2025 was $4.55B, a 73.08% increase from 2024. BeOne Medicines Ltd. cash & equivalents for the quarter ending March 31, 2026 was $4.79B.
What was BeOne Medicines Ltd.'s cash & equivalents in 2024?
BeOne Medicines Ltd. annual cash & equivalents for 2024 was $2.63B, a 17.53% decline from 2023.
What was BeOne Medicines Ltd.'s cash & equivalents in 2023?
BeOne Medicines Ltd. annual cash & equivalents for 2023 was $3.19B, a 17.67% decline from 2022.
What is BeOne Medicines Ltd.'s 5-year cash & equivalents CAGR?
BeOne Medicines Ltd. cash & equivalents grew at a compound annual growth rate (CAGR) of 26.75% from FY2020 to FY2025, going from $1.39B to $4.55B over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $4.55B | +73.1% | 10-K |
| FY2024 | $2.63B | -17.5% | 10-K |
| FY2023 | $3.19B | -17.7% | 10-K |
| FY2022 | $3.87B | -11.7% | 10-K |
| FY2021 | $4.38B | +215.3% | 10-K |
| FY2020 | $1.39B | +123.9% | 10-K |
| FY2019 | $620.8M | -12.9% | 10-K |
| FY2018 | $712.9M | +197.6% | 10-K |
| FY2017 | $239.6M | +173.8% | 10-K |
| FY2016 | $87.5M | +389.8% | 10-K |
| FY2015 | $17.9M | +28.6% | 10-K |
| FY2014 | $13.9M | +254.0% | 10-K |
| FY2013 | $3.9M | - | 10-K |